De nouvelles normes pour les essais cliniques pourraient accélérer le développement de traitements comportementaux contre la démence

Neuropsychiatric symptoms like agitation, psychosis, and apathy affect 80% of dementia patients and are more strongly linked to caregiver burden than cognitive decline itself. Yet only two medications are approved globally for these devastating behavioral symptoms. A comprehensive review by leading dementia researchers outlines how improved clinical trial methodology could accelerate development of new treatments.

The authors applied CONSORT (Consolidated Standards for Reporting Trials) guidelines to neuropsychiatric symptom trials, identifying key innovations needed. Traditional parallel-group placebo-controlled designs often fail due to high placebo response rates. Alternative approaches show promise: randomized discontinuation trials put all participants on active treatment initially, then randomize responders to continue or switch to placebo. Sequential parallel comparison designs re-randomize placebo non-responders, reducing placebo effects in the second stage.

Biomarkers are revolutionizing trial design by enabling precise diagnosis of underlying conditions like Alzheimer's disease, allowing researchers to target specific proteinopathies. The review emphasizes that different neurodegenerative diseases may require tailored approaches - tauopathies often manifest with apathy, while synucleinopathies typically involve hallucinations and delusions.

The guidelines stress using validated rating scales for specific symptoms rather than composite behavioral scores, and recommend Bayesian adaptive designs that allow mid-trial adjustments based on accumulating data. Patient-focused designs should minimize participation barriers while ensuring safety.

These standardized approaches could dramatically improve success rates for trials testing the diverse array of experimental treatments in development, including atypical antipsychotics, muscarinic agonists, cannabinoids, and psychedelics. With dementia cases projected to reach 152.8 million by 2050, establishing rigorous trial standards is crucial for bringing effective behavioral treatments to patients and families facing these challenging symptoms.